All In Biotech

Free tool

FAERS Monitor: Mozobil

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022311 or its brand name (Mozobil, Plerixafor). Reports on generic versions are filed under their own applications.

Reports

1,485

Serious

1,174

79% of reports

Hospitalization

479

Death reported

244

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia144
  • off label use127
  • diarrhoea100
  • pyrexia86
  • mucosal inflammation83
  • nausea82
  • thrombocytopenia82
  • death60
  • plasma cell myeloma60
  • pneumonia58
  • neutropenia57
  • vomiting57
  • dyspnoea55
  • drug ineffective54
  • acute kidney injury46

Reports by year received

View as table
YearReports
200920
201041
201173
2012114
201374
201449
201553
201648
201769
201862
2019107
2020139
2021204
202286
202375
2024127
202594
202650

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,674 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal8345.036.53,524
febrile neutropeniaSignal14430.826.44,128
plasma cell myelomaSignal6021.817.01,171
thrombocytopeniaSignal8210.48.4690
neutropeniaSignal575.94.6231
acute kidney injurySignal464.33.2112
pyrexiaSignal863.52.9155
pneumoniaSignal582.52.053
diarrhoeaSignal1002.21.866
off label useSignal1272.11.771
vomiting571.71.317
nausea821.51.212
dyspnoea551.41.15
death601.00.80
drug ineffective540.60.417

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.